Kornimate/medical-research-clean huggingface dataset:
gastrointestinal motor disorders (esophageal and anorectal) after covid-19

Conditions: Gastrointestinal Motility Disorder

Summary: the patients who had covid-19 infection, and after that reported for one of the signs of gastrointestinal disorder (esophageal and anorectal) will be underwent to esophageal and anorectal motor monitoring investigation (hrm manometry) on standard protocol.

the patients who had covid-19 infection, and after that reported for one of the signs of gastrointestinal (esophageal and anorectal disorder) will be underwent to esophageal and anorectal motor monitoring investigation (hrm manometry) on standard protocol. the patients with dysphagia, chest discomfort during swallowing, or chest pain during swallowing, patients with obstipation, fecal evacuation symptoms, lower stomach discomfort before defecation etc. will be included in the study. in all of them other gastrointestinal diseases will be excluded by standard routine laboratory investigation, ultrasound, routine endoscopy investigation and 24 hours impedance ph-measurement. after manometric measurement of esophagus and anorectal region to standard protocol by using mms-hrm 360 monitoring system with 36 canals catheter for esophagus and 24 canals catheter for anorectal monitoring, data will be calculated by using statistics.

Eligibility criteria:
inclusion criteria: * patients with esophageal and anorectal symptoms after covid 19- infection * patients with worsening of esophageal and anorectal symptom after covid 19- infection, but who had previously described esophageal and anorectal symptoms exclusion criteria: * other gastrointestinal disease that can influence to results * gastroesophageal reflux * h. pylori infection * bacterial, parasitic, viral and fungal gastrointestinal infection or infestation * myasthenia * scleroderma * diabetes mellitus * thyroidal hyperfunction

Keywords: after covid-19 gastrointestinal motility
the validity and reliability study of the chelsea critical care physical assesment tool

Conditions: ICU Patients; ICU Acquired Weakness

Summary: this study is aimed at providing an translation and cross-cultural adaptation of chelsea critical care physical assesment tool (cpax) and tested its reliability and validity.

survival has increased in the icu due to technological developments , but physical disability after discharge has become an important problem. i̇ntensive care unit acquired weakness(icu-aw) is seen in most of the patients admitted in this unit. the biggest reasons for icu-aw are; sepsis, multiple organ failure and prolonged mechanical ventilation. the use of measurement tools to evaluate disabilities during stay and after discharge in intensive care unit, is a subject that has been researched all over the world.. these measurement tools provide; monitoring and evaluation during the icu admission and assessment efficacy of treatment in the unit. the chelsea critical care physical assessment tool(cpax) has been shown to valid, reliable and to exhibited strong clinimetric properties. cpax is a numerical measurement tool, rated according to the 6-point guttman scale, from complete dependence to independence and consist of ten physical function parameters. this study is aimed at providing an translation and cross-cultural adaptation of chelsea critical care physical assesment tool (cpax) and tested its reliability and validity. the protocol includes a pre-test of the turkish version on 10 patients, a final revision, and a validation on a sample of 40 i̇cu patients.

Eligibility criteria:
inclusion criteria: * older than 18 years * critical adult patients * patients who were hospitalized for more than 48 hours in an icu exclusion criteria: * unstable fracture * limb deformities and dysfunction * myasthenia gravis * neuromuscular dysfunction * patients who diagnosed covi̇d-19

Keywords: physical function critical i̇ll icu acquired weakness
accuracy & usability study for soberlink cellular device

Conditions: Substance Abuse

Summary: this study scope is to validate the accuracy and usability of the soberlink cellular device in comparison to a predicate device, bactrack s80 pro.

the purpose of this accuracy and usability study is to validate the performance of soberlink cellular device in the hands of the intended (lay) users - untrained study participants who have consumed alcohol and use the soberlink cellular device to measure their blood alcohol content (bac) in comparison to a predicate device. the purpose of this document is to define how the human factors environment impacts the actual user interface design as well as how usability engineering evaluates user interface via usability objectives and usability tests. this accuracy and usability study will be performed on soberlink cellular device in order to comply with fda's draft guidance for industry and food and drug administration staff, titled: applying human factors and usability engineering to optimize medical device design, iec 60601-1-6 (collateral standard for usability engineering of medical electrical equipment), and iec 62366 (application of usability engineering to medical devices).

Eligibility criteria:
inclusion criteria: * subject willing to sign an informed consent * male or female subject between the ages of 21-99 years old * untrained subject in the use of an alcohol breathalyzer * subject willing to consume two alcoholic drinks * subjects willing to use two alcohol breathalyzers * subject willing to complete a questionnaire exclusion criteria: * subject with previous alcohol breathalyzer experience * subject currently in substance use rehabilitation or post rehabilitation, or unauthorized to consume alcohol for any other reason * subject with lung disease, or is physically unable to provide a deep lung exhalation for 4 seconds * subject unwilling to drink two alcoholic drinks * subject unwilling to complete a questionnaire * subject that is non-english speaking * subject that is a child, adolescent, or cognitively impaired. * subject that is a pregnant and/or breastfeeding woman
the plastic covering method for self-gripping mesh placement in laparoscopic inguinal hernia repair

Conditions: Laparoscopic Inguinal Hernia Repair

Summary: inguinal hernia is one of the most-common surgical conditions. incidence is about 27% in males and 3% in females.the treatment of this condition is inguinal hernia repair operation which can be approached with several techniques; open hernia repair, laparoscopic hernia repair and robotic hernia repair. the current guidelines recommend the hernia repair operation with mesh placement either lichtenstenstein operation or laparoscopic technique; transabdominal preperitoneal technique (tapp) and totally extraperitoneal technique (tep). in the laparoscopic approach, one of the complications that can occur is post-operative pain from the mesh fixator. so the self-gripping mesh becomes another option to decrease this incidence.however the adhesive property of the mesh is still challenging for many surgeons. several techniques of self-gripping mesh placement were introduced. one of the popular techniques is bilateral vertical folding of self-gripping mesh which still causes some adhesive problems when introduced to the target area. this research's aim is to present a new technique of the self-gripping mesh placement which is more effective, more convenient, and decreases the time taken to place the mesh at the surgery site.

a randomized control trail comparing the duration of mesh placement and surgeon satisfaction of self-gripping mesh with plastic sheath and with non-plastic sheath covering mesh. patients with groin hernia who planned for elective laparoscopically repair hernia with self-gripping mesh at ramathibodi hospital, faculty of medicine, mahidol university will are informed of the details of research at the outpatient department before admission. 1:1 open label randomization trail was designed dividing the patients into two groups by the study number. the operation will be done with the standard laparoscopic hernia repair technique by experienced surgeons.

Eligibility criteria:
inclusion criteria: * elective laparoscopic inguinal hernia repair exclusion criteria: * rejected or withdrawn consent

Keywords: inguinal hernia repair laparoscopic inguinal hernia repair self-gripping mesh placement
fdg digital pet/ct as first line investigation for giant cell arteritis

Conditions: Giant Cell Arteritis; Vasculitis

Summary: giant cell arteritis (gca) causes inflammation of the arteries and can lead to serious complications such as blindness, necessitating rapid diagnosis and treatment. although older technology non-digital pet/ct scans are routinely used for the diagnosis of gca in large arteries, they have not been able to reliably detect inflammation of the small arteries responsible for blindness. recent technological advances have enabled pet/ct imaging of millimetric disease in the body, which are now able to resolve small arteries. in the proposed research study, patients who are suspected by their doctors to have gca will undergo an ultrasound of the temporal arteries, and digital pet/ct scan after injection of radioactive glucose. digital pet/ct scans will be interpreted for the presence of abnormal uptake in the large and small arteries, as well as for the presence of other causes of the patient's symptoms. the diagnostic accuracy of pet/ct and ultrasound will be evaluated with respect to an expert panel diagnosis of giant cell arteritis and compared. results will be adjusted for lack of a perfect reference test using advanced statistics. the goal will be to see if digital pet/ct can become a single, integrated test to diagnose this disease.


Eligibility criteria:
inclusion criteria: * age ≥ 50 years, capable and willing to provide informed consent and can tolerate pet/ct. * esr ≥ 50 mm/h and/or crp ≥ 10mg/l within 1 week of pet/ct referral. * new suspected giant cell arteritis according to at least one of the following criteria: cranial gca symptoms (new-onset localized headache, scalp or temporal artery tenderness, ischemia-related vision loss, masseter pain on prolonged mastication) pmr symptoms: shoulder and/or hip girdle pain associated with inflammatory stiffness. suspected large-vessel vasculitis based on angiography, mra, or cta. exclusion criteria: * initiation of corticosteroid or immunosuppressive therapy \>4 days before pet/ct. * prior tab or treated gca with suspected relapse. * non-fasting or hyperglycemia (\>11.1 mmol/l) resulting in altered fdg biodistribution.

Keywords: fdg pet/ct digital pet
exploration of the value of psma pet/ct in dynamic monitoring of the efficacy of novel endocrine therapy in patients with metastatic hormone sensitive prostate cancer

Conditions: Prostate Adenocarcinoma

Summary: 1. based on the treatment response and prognosis of mhspc patients with novel endocrine therapy, a psma pet whole-body tumor burden classification was constructed to guide treatment and evaluate prognosis. 2. based on the treatment response and prognosis of mhspc patients with novel endocrine therapy, a multivariable model will be constructed using quantitative parameters of psma pet/ct imaging, pre-treatment gene status, psa, gs/isup and other clinical pathological parameters to further achieve accurate patient classification, guide treatment, and evaluate prognosis.

1. construction of psma pet whole-body tumor burden classification: 1. assessment of whole-body tumor burden on psma pet/ct images of mhspc patients before new endocrine therapy. 2. psma pet/ct imaging evaluation of treatment response of the first three months after start of new endocrine therapy. 3. based on the response results, the optimal threshold for whole-body tumor burden is obtained through roc curve analysis, and a preliminary classification of whole-body tumor burden is obtained. verification 1: follow up preliminary verification/improvement of this subtype verification 2: external verification, reverifying the predictive performance of typing through the verification cohort. 2. construction of multivariable predictive model for mhspc patients with novel endocrine therapy: 1. molecular imaging parameter measurement and collection of psma pet/ct images of mhspc patients of 3 months after the start of new endocrine therapy. 2. complete pre-treatment genetic testing, dynamic evaluation of serum psa before and after treatment, and collection of clinical and pathological information. 3. based on follow-up results, construct a multi factor model, screen significant factors, and achieve a predictive model for novel endocrine therapy in mhspc patients verification: external verification, verifying the predictive performance of the model through the verification cohort.

Eligibility criteria:
inclusion criteria: * prostate cancer patients confirmed to have metastasis by psma pet/ct before new endocrine therapy. * those who have not undergone androgen deprivation treatment in the past, or have currently received androgen deprivation treatment for no more than 120 days without progress, or have received androgen deprivation treatment in the past (treatment time less than 24 months and no progress within 12 months after completion). * patients with kps score ≥ 50 (ecog/who equivalent). * patient age\>18 years old. exclusion criteria: patients who cannot understand and voluntarily participate in this trial, donnot sign an informed consent form, and aren't able to cooperate independently in completing the examination.
study of the immune response in colon adenocarcinoma

Conditions: Colon Adenocarcinoma

Summary: duration of each part of the study per patient: * screening: from 1 to 4 weeks * sampling period (blood and tissue): 1 day * follow-up by patient: 60 months * total study duration by patient: 84 months * total inclusion duration: 24 months * total follow-up duration: 60 months * total study duration: 84 months


Eligibility criteria:
inclusion criteria: 1. patients aged 18 or more. 2. affiliation to a social security scheme 3. diagnosis of a colon adenocarcinoma. 4. patient have signed and dated consent of the study before undertaking procedures related to the study. exclusion criteria: 1. patients under guardianship / curatorship 2. following situations * persons unable to understand, read and / or sign an informed consent * patient with the following functions: investigator or co-investigator, research assistant, pharmacist, study coordinator or having any involvement in the study * uncooperative person or potentially non-compliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year. * no affiliation to a social security scheme, a universal medical coverage or any similar plan. 3. pregnant or lactating women. 4. patients with hiv seropositivity. 5. rectal tumor location.
prevention of venous thromboembolism in patients undergoing elective total knee replacement surgery

Conditions: Venous Thromboembolism

Summary: the primary objective was to demonstrate the dose-response of semuloparin sodium (ave5026) for the prevention of venous thromboembolism \[vte\] in patients undergoing total knee replacement \[tkr\] surgery. secondary objectives were to evaluate the safety (incidence of major bleeding) of ave5026, to document the efficacy and safety of ave5026 post-operative regimens, and to assess the pharmacokinetic parameters of ave5026.

the randomization had to take place before the first study drug injection. the total duration of observation per participant was 27-33 days from surgery broken down as follows: * 4 to 10-day double-blind treatment period; * follow-up period up to day 30 ± 3 after surgery. mandatory bilateral venography of the lower limbs had to be performed between 5 to 11 days after surgery.

Eligibility criteria:
inclusion criteria: * patient scheduled to undergo elective total knee replacement or revision of a primary procedure performed ≥ 6 months prior to study entry. exclusion criteria: * any major orthopedic surgery in the 3 months prior to study entry; * clinical signs or symptoms of dvt or pe within the last 12 months or known post-phlebitic syndrome; * known sensitivity to iodine or contrast dyes; * recent stroke or myocardial infarction; * high risk of bleeding; * treatment with other anti-thrombotic agents within 7 days prior to surgery; * any contra-indication to unfractionated heparin or low molecular weight heparin; * pregnant or nursing woman, or woman of childbearing potential who is not using an effective contraceptive method. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: prevention venous thrombosis orthopedic surgery
acupressure for fatigue in ovarian cancer survivors

Conditions: Fatigue; Ovarian Cancer

Summary: the purpose of this study is to see if accupressure can help reduce the severity of fatigue experienced by ovarian cancer patients. acupressure involves applying mild to moderate physical pressure by fingers, hand or a device to specific points on the skin to try to bring about a change in the body's functioning, in this case relief from chronic fatigue.


Eligibility criteria:
inclusion criteria: * women aged 21 and older * diagnosis of ovarian cancer, stages i to iv * have average persistent fatigue defined a \>=4 on the brief fatigue inventory. * fatigue must have started at or after the diagnosis of ovarian cancer * completed all primary cancer treatments (surgery, chemotherapy at least 6 months prior), except maintenance therapies * no other planned interventions for fatigue other than current stable medication exclusion criteria: * medically unstable * acupuncture or acupressure receipt in past year * have a diagnosis of untreated mood disorder, e.g., bipolar or major depressive disorder * have a current diagnosis of anemia * have a current untreated diagnosis of hypothyroidism * have an initiation, a cessation or change of treatment of any chronic medications, dietary supplements, behavioral therapy, physical therapy, etc., or any planned change of medications, supplements or therapies during the study * have the possibility of becoming pregnant

Keywords: acupressure
evaluation of extended wear hearing aid for mild hearing loss

Conditions: Sensorineural Hearing Loss

Summary: this study will assess the benefit of extended wear hearing aids for subjective listening effort, compared to the unaided condition, in adults with mild sensorineural hearing loss.

this study will assess the benefit of extended wear hearing aids for subjective listening effort, compared to the unaided condition, in adults with mild sensorineural hearing loss. participants will be experienced hearing aid users who have previously worn or currently wear extended wear hearing devices. the primary objective will be to assess subjective listening effort, compared to unaided.

Eligibility criteria:
inclusion criteria: * meets requirements outlined on lyric candidacy form * current lyric hearing instrument user * 18 years of age or older at time of enrollment in the study * mild sensorineural hearing loss as defined by who, 4 frequency pta of 20-34 db hl, in the better hearing ear * good understanding (read/write/speak) of the english language * willingness to comply with all study requirements exclusion criteria: * does not meet requirements outlined on lyric candidacy form (see chapter 9 of the tmf/isf for srf-469) * difficulty understanding/reading instructions when corrected for vision loss * impairments that would restrict participation in any of the evaluations * ear health conditions present at baseline that prevent immediate device replacement * conditions that would indicate the need for medical referral prior to hearing aid fitting, according to clinic's standard protocol

Keywords: extended wear hearing aid
phase ii study of kps-0373 in patients with spinocerebellar degeneration (scd)

Conditions: Spinocerebellar Degeneration

Summary: to evaluate the efficacy, safety and pharmacokinetics profile of kps-0373 in patients with scd


Eligibility criteria:
inclusion criteria: * scd with mild to moderate ataxia exclusion criteria: * patients with secondary ataxia * patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Keywords: spinocerebellar degeneration thyrotropin-releasing hormone (trh) scd
anterior component separation versus posterior component separation for repair of large ventral hernias

Conditions: Large Midline Ventral Hernia

Summary: this study evaluates effect of anterior component separation and posterior component separation and transversus abdominis muscle release methods for treatment of midline ventral hernias.

the anterior component separation technique requires an extensive subcutaneous flap elevation, incision of the external oblique aponeurosis, and incision of the posterior rectus sheath. the posterior component separation technique utilized the retromuscular space, accessed by incising the posterior rectus sheath and dissecting the posterior sheath between the internal oblique and transversus abdominis muscles. transversus abdominis muscle release dissected the posterior sheath back to the transversus abdominal muscle and accessed the space between muscle and trasversalis fascia.

Eligibility criteria:
inclusion criteria: * subject has midline ventral hernia * patient's approval to participate in the study exclusion criteria: * strangulated hernia * patient's preference for either operative technique * patient's refusal to participate in the study

Keywords: anterior component separation, tar
a study of the safety and tolerability of pimavanserin (acp-103) in patients with parkinson's disease psychosis

Conditions: Parkinson's Disease Psychosis

Summary: to assess the long-term safety and tolerability of acp-103 in subjects with parkinson's disease psychosis.

this study did not have a fixed duration, and the duration of individual subject participation was determined based on investigator assessment of subject tolerability and continued benefit until such time as either the drug was commercially available in the us, or an alternate treatment extension was available in non-us regions. for this reason, no subjects, therefore, were considered to have "completed" the study.

Eligibility criteria:
inclusion criteria: * subject has completed the treatment period of a previous blinded study of pimavanserin * the subject is willing and able to provide consent * caregiver is willing and able to accompany the subject to all visits exclusion criteria: * subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder * subject is judged by the investigator to be inappropriate for the study

Keywords: parkinson's disease psychosis